Trial Profile
Phase II study of OSI-774 (erlotinib, Tarceva) in elderly patients with advanced stage or inoperable non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Dec 2019
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Dec 2019 Status changed from suspended to completed.
- 10 Dec 2005 New trial record.